Skip to Content

Extina Approval History

FDA Approved: Yes (First approved June 12, 2007)
Brand name: Extina
Generic name: ketoconazole
Dosage form: Foam
Company: Stiefel Laboratories, Inc.
Treatment for: Seborrheic Dermatitis

Extina Foam is a topical formulation of the antifungal ketoconazole in VersaFoam for the treatment of seborrheic dermatitis.

Development History and FDA Approval Process for Extina

DateArticle
Jun 13, 2007Approval FDA Approves Extina for the Treatment of Seborrheic Dermatitis
Nov 24, 2004Connetics Receives FDA Non-Approvable Letter for Extina
Apr  8, 2004Connetics' New Drug Application for Extina Has Been Accepted for Filing by the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide